Aptevo Therapeutics (APVO) Free Cash Flow (2016 - 2023)
Historic Free Cash Flow for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to -$6.2 million.
- Aptevo Therapeutics' Free Cash Flow rose 956.52% to -$6.2 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$12.4 million, marking a year-over-year increase of 3494.37%. This contributed to the annual value of -$11.7 million for FY2023, which is 4427.82% up from last year.
- As of Q3 2023, Aptevo Therapeutics' Free Cash Flow stood at -$6.2 million, which was up 956.52% from -$4.8 million recorded in Q2 2023.
- Aptevo Therapeutics' 5-year Free Cash Flow high stood at $4.6 million for Q1 2023, and its period low was -$15.9 million during Q2 2019.
- Over the past 5 years, Aptevo Therapeutics' median Free Cash Flow value was -$5.9 million (recorded in 2022), while the average stood at -$6.4 million.
- Within the past 5 years, the most significant YoY rise in Aptevo Therapeutics' Free Cash Flow was 18923.2% (2023), while the steepest drop was 5644.95% (2023).
- Over the past 5 years, Aptevo Therapeutics' Free Cash Flow (Quarter) stood at -$5.1 million in 2019, then fell by 20.06% to -$6.1 million in 2020, then skyrocketed by 34.71% to -$4.0 million in 2021, then crashed by 48.55% to -$5.9 million in 2022, then decreased by 5.07% to -$6.2 million in 2023.
- Its Free Cash Flow was -$6.2 million in Q3 2023, compared to -$4.8 million in Q2 2023 and $4.6 million in Q1 2023.